Product Identifier: LIDOCAINE HCI INJECTION + EPINEPHRINE

MATERIAL SAFETY DATA SHEET

DIN #: 00141984

SECTION 1 – PRODUCT IDENTIFICATION AND USE					
MANUFACTURER'S NAME:	BIMEDA-MTC ANIMAL HEALTH INC.		SUPPLIER'S NAME:		BIMEDA-MTC ANIMAL HEALTH INC.
STREET ADDRESS:	420 BEAVERDALE ROAD		STREET ADDRESS:		420 BEAVERDALE ROAD
CITY AND PROVINCE:	CAMBRIDGE, ONTARIO		CITY AND PROVINCE:		CAMBRIDGE, ONTARIO
POSTAL CODE:	N3C 2W4		POSTAL CODE:		N3C 2W4
TELEPHONE #	519-654-8000		TELEPHONE #		519-654-8000
EMERGENCY RESPONSE:	CHEMTREC		TELEPHONE #		1-800-424-9300
CHEMICAL NAME:		CHEMICAL FAMILY:		CHEMICAL FOR	RMULA:
PRODUCT CODE: 1LID009 1LID010			PRODUCT	Γ SIZE: 100 ml 250 ml	

SECTION 2 – SIGNIFICANT COMPONENTS				
COMPONENT	OSHA PEL	ACGIH	OTHER	% (OPTIONAL)
TLV LIMITS				
Lidocaine Hydrochloride	Not Listed	Not Listed	None	2.25
(CAS# 73-78-9)				
Epinephrine	Not Listed	Not Listed	None	0.002
(CAS# 51-43-4)				

SECTION 3 – PHYSICAL DATA						
PHYSICAL STATE:		ODOUR AND APPEARANCE:		ODOUR THRESHOLD (ppm):		
Liquid.		Clear, colourless, odourless liquid.				
VAPOUR PRESSURE (mm Hg):		VAPOUR DENSITY (Air = 1):		EVAPORATION RATE (Ether = 1):		
~17		0.6		~1		
BOILING POINT (DEG.C):		MELTING POINT (DEG. C):		CRITICAL TEMPERATURE:		
100 deg C		N/A				
pH (100%):	SPECIFIC	C GRAVITY (H2O = 1): SOLUBIITY IN WA		ATER:	COEFF: WATER/OIL DIST.:	
	~1		Soluble			

CECTION 4 FIRE AND EVELOCION DATA						
SECTION 4 – FIRE AND EXPLOSION DATA						
FLAMMABLE:						
IF YES, UNDER WHICH CONDITIONS:						
MEANS OF EXTINCTION: Water spray.						
SPECIAL FIRE FIGHTING PROCEDURES: None						
UNUSUAL FIRE AND EXPLOSION HAZARDS: None						
FLASHPOINT (Deg. C) AND METHOD:	UPPER FLAMMABLE LIMIT	LOWER FLAMMABLE LIMIT				
	(% BY VOLUME):	(% BY VOLUME):				
Not flammable.	N/A	N/A				

Product Identifier: LIDOCAINE HCI INJECTION + EPINEPHRINE DIN #: 00141984

SECTION 5 - REACTIVITY DATA

CHEMICAL STABILITY - (IF NO, UNDER WHICH CONDITIONS?)

Stable

INCOMPATIBILITY WITH OTHER SUBSTANCES (IF YES, WHICH ONES?)

Compounds which react violently with water.

CONDITIONS TO AVOID:

N/A

HAZARDOUS DECOMPOSITION PRODUCTS:

None

HAZARDOUS POLYMERIZATION::

Will not occur.

SECTION 6 – TOXICOLOGICAL PROPERTIES

ROUTE OF ENTRY:

Skin: Yes Skin Absorption: () Eye: Yes

HEALTH HAZARDS (ACUTE AND CHRONIC):

Ingestion and systemic absorption may result in toxic effects to the central nervous system and to the cardiovascular system. Allergic reactions may also occur. Significant adverse effects on intact skin unlikely. Contact with mucous membranes and/or eyes may cause irritation with numbness and loss of sensation.

CARCINOGENICITY:

Not listed.

SIGNS AND SYMPTOMS OF EXPOSURE:

Ingestion and systemic absorption may result in toxic effects to the central nervous system and to the cardiovascular system. Allergic reactions may also occur. Significant adverse effects on intact skin unlikely. Contact with mucous membranes and/or eyes may cause irritation with numbness and loss of sensation.

MEDICAL CONDITIONS GENERALLY AGGRAVATED BY EXPOSURE:

Hypersensitivity to amide-type local anesthetics.

EMERGENCY AND FIRST AID PROCEDURES:

Notify physician or poison control center immediately. Medical attention should include maintenance of breathing and control of convulsions, if they occur. If eye contact occurs, wash thoroughly with clean water for 15 minutes.

SECTION 7 – PREVENTATIVE MEASURES

PERSONAL PROTECTIVE EQUIPMENT:

RESPIRATORY PROTECTION (Specify):

Not normally required.

VENTILATION:
Local exhaust.

Rubber gloves recommended, especially over abraded skin.

WORK/HYGIENIC PRACTICES:

Avoid ingestion and contact with eyes. Wash hands and face before eating, drinking or smoking.

ENGINEERING CONTROLS:

LEAK AND SPILL PROCEDURES: Follow normal procedures used for clean up of non-hazardous liquids.

WASTE DISPOSAL: Dispose as non hazardous waste at facility operating in compliance with applicable federal state and local regulations.

STORAGE AND HANDLING REQUIREMENTS: Store in a cool, dry place. Avoid extremes in temperature. Handle to avoid breakage.

OTHER PRECAUTIONS: Avoid contact with eyes, mucous membranes, abraded skin.

Product Identifier: LIDOCAINE HCI INJECTION + EPINEPHRINE

SECTION 8 – PREPARATION DATA						
DATE:		TELEPHONE NUMBER:	519-654-8000			
DATE UPDATED	September 2005, June 2008, August 2009, August 2010, May 2014					

DIN #: 00141984

Information for this material safety data sheet was obtained from sources considered technically accurate and reliable. While every effort has been made to ensure full disclosure of product hazards, in some cases data is not available and is so stated. Since conditions of actual product use are beyond the control of the supplier, it is assumed that user of this material has been fully trained according to the mandatory requirements of WHMIS. No warranty, expressed or implied, is made and supplier will not be liable for any losses, injuries or consequential damages which may result from the use of or reliance on any information contained in this form. If user requires independent information on ingredients in this or any other material, we recommend contact supplier.